CompletedPhase 2NCT04625985

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Laboratorios Silanes S.A. de C.V.
Principal Investigator
Janet Silvia M Aguirre, MD
The American British Cowdray Medical Center. I.A.P.
Intervention
Metformin Glycinate(drug)
Enrollment
20 target
Eligibility
18 years · All sexes
Timeline
20202021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04625985 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials